TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00644540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Trivalent Inactivated Vaccines
Description: This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Trivalent Inactivated Vaccines
Description: This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm.
Study: NCT02062151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture
Study: NCT00918762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic endoscopic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic endoscopic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted surgery
Study: NCT00855530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amibegron (SR58611A)
Description: oral administration of 300 mg twice daily
Study: NCT02638428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT03960021

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RFA interventions
Description: Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
Study: NCT01120834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: * Dose level 1: azacitidine 55 mg/m2 on days 1-5~* Dose level 2: azacitidine 75 mg/m2 on days 1-5~* Dose level 3: azacitidine 55 mg/m2 on days 1-5~* Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles.
Study: NCT00213590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
Study: NCT03284138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS treatment
Description: patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
Study: NCT01120834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: * Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~* Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~* Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~* Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles.
Study: NCT01858636

Intervention type: DEVICE
Intervention: Angio-Seal VIP 6 French (6F) and 8 French (8F) devices
Description: These devices are used for the vascular closure procedure
Study: NCT04470921

Intervention type: PROCEDURE
Intervention: Opportunistic Salpingectomy
Description: An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
Study: NCT01765803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mellaril
Description: Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
Study: NCT01661816

Intervention type: BEHAVIORAL
Intervention: interview
Description: psychological, emotional, family and social parameters

Intervention type: BEHAVIORAL
Intervention: interview
Description: psychological, emotional, family and social parameters

Intervention type: BEHAVIORAL
Intervention: interview
Description: psychological, emotional, family and social parameters

Intervention type: BEHAVIORAL
Intervention: interview
Description: psychological, emotional, family and social parameters

Intervention type: BEHAVIORAL
Intervention: interview
Description: psychological, emotional, family and social parameters
Study: NCT04172662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Music Listening
Description: The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
Study: NCT00812344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0837
Description: Oral solution, dosing through the Loc-I-Gut catheter, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0837
Description: Oral solution, dosing through the Loc-I-Gut catheter, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: tablets, orally, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole
Description: dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
Study: NCT00806507

Intervention type: PROCEDURE
Intervention: Echocardiograms
Description: Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.

Intervention type: PROCEDURE
Intervention: Blood Test
Description: Measuring of hormones and metabolic proteins (such as sugars and acids).
Study: NCT03192878

Intervention type: DRUG
Intervention: Infliximab
Description: infliximab biosimilar

Intervention type: DRUG
Intervention: Infliximab
Description: infliximab biosimilar
Study: NCT03364907

Intervention type: OTHER
Intervention: HIPEC with flushing afterwards
Description: flushing with saline fluid after HIPEC

Intervention type: OTHER
Intervention: HIPEC without flushing afterwards
Description: NO flushing with saline fluid after HIPEC
Study: NCT04143529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized acceptance-based mindfulness exercise
Description: The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief educational pamphlet
Description: The control condition will be educational information on pain and stress that patients will read over within 60 seconds
Study: NCT03709329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Gait Therapy
Description: The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Therapy
Description: The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
Study: NCT02732743

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Physiomanna® Baby
Description: Dosage 1g/kg body, 2 cycles (if applicable)
Study: NCT00939952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ertapenem
Description: 500 mg IV once
Study: NCT01689961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured + monitored nutrition and exercise intervention
Description: The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
Study: NCT01057901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin
Description: Flibanserin 100mg administered at bedtime for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the matched placebo which will be administered two tablets daily at bedtime.
Study: NCT00999921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil
Description: Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
Study: NCT02129660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 of glycopyrrolate, 2.0% QD
Description: Dose 1 of glycopyrrolate Topical Wipes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 of glycopyrrolate, 3.0% QD
Description: Dose 2 of glycopyrrolate Topical Wipes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose 1 of glycopyrronium, 2.5% QD
Description: Dose 1 of glycopyrronium Topical Wipes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose 2 of glycopyrronium, 3.75% QD
Description: Dose 2 of glycopyrronium Topical Wipes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Topical Wipes
Study: NCT03494348

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Congruent Polyethylene (MC)
Description: One group receives the conventional CR surface and the other the new MC articular surface
Study: NCT01712321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone 20mg or 40mg taken once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
Study: NCT03284138

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo treatment
Description: patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
Study: NCT04322513

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers expression
Description: Evaluation in biomarkers expression between 2 groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers expression
Description: Evaluation in biomarkers expression between 2 groups
Study: NCT04737239

Intervention type: OTHER
Intervention: Corticosteroid injections for CTS treatment
Description: Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients

Intervention type: OTHER
Intervention: Corticosteroid injections for CTS treatment
Description: Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
Study: NCT01204138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Apremilast 30mg BID
Study: NCT04044079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT00430378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: No Acupuncture.
Study: NCT04053283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NG-641
Description: NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
Study: NCT01204138

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT02664792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma
Study: NCT01395017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT03954067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP9801
Description: Administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP9801
Description: Administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP9801
Description: Administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP9801
Description: Administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP9801
Description: Administered by intratumoral injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by Intravenous Infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by Intravenous Infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by Intravenous Infusion
Study: NCT01395017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01783392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Study: NCT01714141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component, technology based intervention
Description: Motivational sessions were adapted from work done with young adults with HIV (MESA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma education active control
Study: NCT02238587

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ganoderma Spores Powder Capsules
Description: In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ganoderma Spores Powder Capsules
Description: In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
Study: NCT02655393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure
Study: NCT03859856

Intervention type: OTHER
Intervention: hormone panel and ultrasonography
Description: Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
Study: NCT04164706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HumiGard device
Description: HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care (with sham HumiGard device)
Description: Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
Study: NCT02687958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Maintenance therapy
Study: NCT02817828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Study: NCT03610607

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intense education
Description: we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intense education
Description: we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
Study: NCT02099318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active SRP cases
Description: The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control cases
Description: Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
Study: NCT01257984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-5300
Description: 0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-5300
Description: 0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
Study: NCT02655393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure
Study: NCT04031235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Baby, Safe and Snug
Description: Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Read Baby, Every Day
Description: Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
Study: NCT02655393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure
Study: NCT00046111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: A topoisomerase I inhibitor used for ovarian and lung cancer treatment
Study: NCT03986515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib plus SHR-1210
Description: apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
Study: NCT01654796

Intervention type: DEVICE
Group type: OTHER
Intervention: Low Field Magnetic Stimulation (LFMS)
Description: The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.